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Abstract
Background: Plasma exchange (PLEX) has been used routinely for treatment of severe renal vasculitis and/or
alveolar haemorrhage (AH) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but the
long-term benefit of PLEX in AAV remains unclear. We aimed to describe the characteristics and outcomes of
patients treated with PLEX in a single centre.
Methods: Patients with AAV were identified by performing a case review of medical records of 705 patients who
received PLEX in a single tertiary referral centre between 2000 and 2010. Patient characteristics and outcomes were
recorded. The Kaplan-Meier method, log-rank tests and Cox regression analysis were used for survival analyses.
Results: A total of 94 patients with AAV were identified (44 men, 50 women; median age 60 years, range 21–90
years; 52 proteinase 3-ANCA, 41 myeloperoxidase-ANCA and 1 ANCA-negative; 8 double-positive for ANCA and
anti-glomerular basement membrane; 93 newly diagnosed/1 relapse; 55 [58.5 %] required dialysis). The reasons for
initiating PLEX therapy were severe renal involvement alone in 52 %, AH in 10 %, both renal involvement and AH in
35 %, and “other” in 3 %. The patients had 3–27 (median 7) PLEX sessions. At 3 months, 81 (86 %) of 94 were alive
and 62 (66 %) of 94 were alive and dialysis-independent. The median follow-up was 41 months (minimum-maximum
0.5–137 months), when 56 (59.6 %) of 94 patients were alive and 47 (50 %) were dialysis-independent. The estimated
overall survival rates were 75.3 % at 1 year and 61.1 % at 5 years. Patient survival decreased with increasing age at
presentation (5-year survival 85 % for age <50 years, 64.4 % for ages 50–65 years, and 41 % for >65 years; p < 0.01 for
comparison between all groups). Estimated renal survival rates were 65.5 % at 1 year and 43 % at 5 years. Renal survival
was worse in patients aged >65 years than in the younger patients (5-year survival 25.1 % in patients >65 years vs. 50.
8 % for those ≤65 years, p < 0.01). The estimated renal survival was better in patients with higher Disease Extent Index
(DEI) >6 than in patients with DEI ≤6 (5-year survival 52.1 % vs. 39.4 %, p = 0.04), even though this was not confirmed
in multivariate analysis.
Conclusions: The mortality of patients presenting with severe manifestations of AAV remains high despite the use of
PLEX. Older age at presentation is associated with worse overall and renal prognosis.
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Background
Anti-neutrophil cytoplasmic antibody-associated vasculitis
(AAV) represents a group of autoimmune diseases, most
(90–95 %) of which are associated with the presence of cir-
culating anti-neutrophil cytoplasmic antibodies (ANCA).
Three types of AAV can be distinguished: (1) microscopic
polyangiitis, (2) granulomatosis with polyangiitis (formerly
called Wegener’s granulomatosis), and (3) eosinophilic
granulomatosis with polyangiitis (Churg-Strauss syndrome)
[1]. Pauci-immune glomerulonephritis with various impair-
ment of kidney function occurs in approximately 70 % of
patients with AAV, and renal insufficiency constitutes a key
determinant of increased AAV mortality.
ANCA likely contributes to disease pathogenesis in
AAV [2], but this remains controversial. The antibodies
have high molecular weight, low volume of distribution,
long half-lives and low turnover rates. These factors
make them a good target for therapeutic plasma ex-
change (PLEX) and support the use of PLEX in the
treatment of AAV. The rapid removal of ANCA may re-
sult in rapid control of disease activity and prevent the
accumulation of organ damage.
In the Plasma Exchange or High Dose Methyl
Prednisolone as Adjunctive Therapy for Severe Renal
Vasculitis (MEPEX) randomised trial, patients with severe
renal vasculitis who received PLEX as adjunctive therapy
had higher probability of dialysis independence at 1 year
than patients treated with high-dose methylprednisolone
(59 % vs. 43 % surviving dialysis-independent patients) [3].
Therapeutic PLEX has been recommended for the
treatment of severe renal vasculitis (serum creatinine
[S-creatinine] >500 μmol/L) [4, 5]. The benefit of PLEX in
the treatment of alveolar haemorrhage (AH) or other se-
vere organ manifestations is less clear, however. Moreover,
the long-term outcomes of patients treated with PLEX in
the MEPEX trial did not differ from the other arm in terms
of both renal and patient survival [6]. A multicentre
international randomised controlled trial, Plasma Exchange
and Glucocorticoids for Treatment of Anti-Neutrophil
Cytoplasm Antibody (ANCA)-Associated Vasculitis
(PEXIVAS), is in progress to establish the efficacy of PLEX
in reducing death and end-stage renal disease in patients
with AAV with an estimated glomerular filtration rate
(GFR) ≤50 ml/minute and/or AH [7]. Until the results of
that trial are available, however, there is no controlled trial
evidence for PLEX in the treatment of AH. In the present
study, we retrospectively assessed characteristics and out-
comes of patients who received PLEX for the treatment of
diagnosed AAV in a single centre between 2000 and 2010.
Methods
Patient characteristics and clinical data
A retrospective analysis of medical records from a dialy-
sis unit was performed for 705 consecutive patients who
were treated with at least one membrane PLEX in a sin-
gle tertiary referral centre between 2000 and 2010. Pa-
tients matching the definitions of AAV according to the
EMA (European Medicines Agency) algorithm [8] were
selected from the database. Patients who were double-
positive for ANCA and anti-glomerular basement mem-
brane (anti-GBM) with predominant anti-GBM and/or
who displayed typical features of anti-GBM disease were
excluded from the study. This study conformed to gen-
erally applied ethical principles and the Declaration of
Helsinki. Data collection was performed within a larger
project entitled Registry of ANCA-Associated Vasculitis.
Informed consent was obtained from all patients, and
the study was approved by the ethics committee of Gen-
eral University Hospital in Prague.
Data collection included baseline characteristics
(vasculitis type and duration, type of ANCA, concomi-
tant positivity of anti-GBM antibodies, organ involve-
ment and renal function); data regarding PLEX sessions
(number and type of procedures, complications); im-
munosuppressive treatment; outcome data (patient and
renal survival) at 3, 6, 12 and 36 months and the most
recent visit; and complications (infections, cardiovascu-
lar morbidity, cause of death).
Active organ involvement was retrospectively assessed
with the use of the Disease Extent Index (DEI), which
can range between 0 and 21 [9]. DEI was preferred to
Birmingham Vasculitis Activity Score (BVAS) because of
the retrospective data collection and lower risk of mis-
scoring with DEI. Severe renal involvement was defined
as the need for haemodialysis or S-creatinine above
500 μmol/L, or as GFR below 20 ml/minute together
with either clinical evidence of rapid progression or se-
vere finding in the renal biopsy. AH was defined as the
presence of diffuse pulmonary infiltrates on a chest x-
ray or computed tomographic scan and either observed
haemoptysis or unexplained anaemia (<100 g/L)/docu-
mented drop in haemoglobin (>10 g/L) from <100 g/L.
Immunosuppressive treatment
All patients were treated with combined immunosup-
pressive treatment consisting of corticosteroids (typically
started with three pulses of intravenous methylpredniso-
lone followed by oral prednisone) and cyclophosphamide
(CYC) given as an oral daily dose of 2 mg/kg/day
(preferred until 2002) or (since 2003) as intravenous
pulses of 15 mg/kg/pulse every 2–3 weeks (with dose re-
duction based on age and renal function) [10]. CYC was
administered for 3–6 months, and then the patients
were switched to azathioprine, typically used for 2 years.
For patients using allopurinol or patients intolerant of
azathioprine, mycophenolate mofetil was used as the
maintenance agent. Prophylaxis of Pneumocystis jirovecii
with co-trimoxazole was routinely used.
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Plasma exchange
PLEX was used as an adjunctive therapy added to stand-
ard immunosuppression. In this study, PLEX was per-
formed by using a filter separation technique in all
patients. The most common PLEX dose included seven
PLEX sessions performed within 14 days (based on the
regimen used in the MEPEX trial [3]), with possible dose
reduction or prolongation according to the patient’s clin-
ical status. The exchanged volume was calculated using
a nomogram (with calculation based on gender, body
height and weight, and haematocrit) and corresponded
to one plasma volume per one session. A central venous
catheter (11.5-French), preferably inserted into the right
internal jugular vein, was used as vascular access in all
patients. Standard anti-coagulation was provided by
administering heparin; the initial dose was 35 IU per
kilogram of body weight, and the dose of about 10–
20 IU/kg body weight/h was administered during each
session, adapted according to the patient’s partial
thromboplastin time.
Until 2004, fresh frozen plasma was preferably used as
the replacement solution. Since then, 5 % albumin has
been used routinely, and fresh frozen plasma is used only
in patients with severe active bleeding (e.g., pulmonary
haemorrhage). Blood pressure, body temperature and
heart rate were regularly monitored during each proced-
ure. The frequency of monitoring of coagulation parame-
ters, blood count, ANCA and total immunoglobulin levels
differed with respect to each patient’s status.
Statistical analysis
Continuous variables are presented as mean ± SD if nor-
mally distributed or as median (minimum-maximum) if
skewed. Kaplan-Meier survival curves, log-rank tests and
Cox regression analysis were used to assess survival. A




A total of 94 patients with AAV were identified. Basic
patient characteristics are displayed in Table 1. All but
one patient received PLEX at the time of diagnosis, and
one patient was treated at relapse. Of 94 patients, 8 were
double-positive for ANCA and anti-GBM; four these
were proteinase 3 (PR3)-ANCA-positive and four were
myeloperoxidase (MPO)-ANCA-positive. The most
common reason for PLEX therapy was severe renal in-
volvement (either alone or in combination with AH),
which was present in 87 % of patients. Active renal in-
volvement was present in 97 % patients; lung involve-
ment in 65 %; and ear, nose and throat involvement in
27 %. The patients received 3–27 PLEX sessions (median
7, interquartile range 6–9).
Outcomes
The median time of follow-up was 41 months (min-max
0.5–137 months), when 56 (59.6 %) of 94 patients were
alive and 47 (50 %) were dialysis-independent. At
3 months, 81 (86 %) of 94 were alive and 62 (66 %) of 94
were alive and dialysis-independent (Table 2).
Overall survival
The estimated overall survival rates were 75.3 % at 1 year
and 61.1 % at 5 years (Fig. 1). The estimated 5-year sur-
vival rates were better in younger patients than in the
older ones (85 % in patients <50 years, 64.4 % in pa-
tients aged 50–65 years and 41 % in patients >65 years;
p < 0.01 for comparison between all groups) (Fig. 2).
Age remained also the only significant risk factor for
death in both univariate and multivariate Cox regression
models (relative risk [RR] 2.9, 95 % CI 1.5–5.8, p < 0.01
when age groups ≤65 and >65 years were used in the
model). No difference in overall survival was found
between patients with S-creatinine below or above
500 μmol/L. Survival did not differ in the groups with
Table 1 Baseline patient characteristics
Patient characteristics (n = 94) Data
Male gender, n (%) 44 (47 %)
Age, years, median (min-max) 60 (21–90)
ANCA type
PR3, n (%) 47 (50 %)
MPO, n (%) 37 (39 %)
Negative, n (%) 1 (1 %)
Double-positive for ANCA and anti-GBM, n (%) 8 (9 %)
Reason for PLEX
Severe renal involvement without AH, n (%) 49 (52 %)
AH without severe renal involvement, n (%) 9 (10 %)
Both severe renal involvement and AH, n (%) 33 (35 %)
Other, n (%) 3 (3 %)
Serum creatinine in non-dialysed, median (min-max) 369 (40–693)
Patients on dialysis, n (%) 55 (59 %)
Active organ involvement
Kidney, n (%) 91 (97 %)
Lungs, n (%) 61 (65 %)
ENT, n (%) 25 (27 %)
Eyes, n (%) 5 (5 %)
Skin, n (%) 9 (10 %)
Peripheral nervous system, n (%) 7 (7 %)
Other, n (%) 3 (3 %)
Abbreviations: AH alveolar haemorrhage, ANCA anti-neutrophil cytoplasm anti-
bodies, ENT ear, nose and throat, GBM glomerular basement membrane, max
maximum, min minimum, MPO myeloperoxidase, PLEX plasma exchange, PR3
proteinase 3
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different antibodies (PR3 vs. MPO vs. double-positive
anti-GBM and ANCA) or between patients with vs. with-
out AH (detailed data not shown). We also did not find
any difference in overall survival between patients diag-
nosed in the 2000–2005 period vs. 2006–2010.
Renal survival
Estimated renal survival rates at 1 year were 65.5 % and
43 % at 5 years. Renal survival was worse in patients
older than 65 years of age than in the younger ones (5-
year survival 25.1 % in patients >65 years old vs. 50.8 %
in patients aged ≤65 years, p < 0.01). No difference in
renal survival was found in subgroups with different S-
creatinine levels below or above 500 μmol/L. The renal
survival did not differ in the groups with different anti-
bodies (PR3 vs. MPO vs. double anti-GBM and ANCA).
Using Kaplan-Meier analysis, no difference in renal sur-
vival was found between patients with and without AH,
however, the renal survival was better in patients with
higher DEI (above 6) than in patients with DEI ≤ 6 (5-
year survival 52.1 % vs. 39.4 %, p = 0.04) (Fig. 3). More
patients with lower DEI required dialysis at entry (45 of
68) than among the group of patients with a higher DEI
(10 of 26, p = 0.02). In the multivariate analysis, the DEI
was not confirmed as an independent risk factor for
renal death.
Causes of death
The leading cause of death was infection (observed in 18
patients), followed by cardiovascular causes (7 patients).
In ten patients, the cause of death was not known or
was unavailable. The remaining causes of death were ob-
served in individuals only (one malignancy, one liver fail-
ure, one haemorrhagic shock).
Discussion
PLEX has been used routinely in the treatment of severe
manifestations of ANCA-associated vasculitides, but evi-
dence from randomised trials supporting its long-term
benefit is missing. Moreover, the situation in randomised
clinical trials is always artificial, and there is a bias to-
wards the selection of “healthier” and/or “more compli-
ant” patients. Thus, the assessment of outcomes in a real
situation in clinical practice is very important and pro-
vides information on the routine use of PLEX in patients
with AAV. In this study, we included a large cohort of
patients with AAV treated with PLEX in a single centre,
and the results show that the mortality of patients
Table 2 Outcome data for patient and renal survival
Absolute time since PLEX Surviving, n (%) RRT in survivors, n (%)
0 months (n = 94) 94 (100 %) 55 (58.5 %)
3 months (n = 94) 81 (86.2 %) 19 (23.5 %)
1 year (n = 94) 68 (72.3 %) 14 (20.6 %)
3 years (n = 79) 49 (62 %) 9 (18.4 %)
5 years (n = 61) 26 (42.6 %) 5 (19.2 %)
End of follow-up (n = 94) 56 (59.6 %) 9 (16.1 %)
PLEX plasma exchange, RRT renal replacement therapy
Fig. 1 Estimated overall patient survival (dotted lines represent 95 % CI)
Fig. 2 Significant difference in estimated overall patient survival in
different age groups (red line <50 years, green line 50–65 years and
blue line >65 years)
Fig. 3 Difference in estimated renal survival in patients with Disease
Extent Index (DEI) ≤6 (red line) vs. DEI >6 (blue line)
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presenting with severe manifestations of AAV remains
high despite the use of PLEX.
Even though direct comparison is difficult because the
patients’ characteristics differed, our results regarding
long-term patient survival were generally similar to or
slightly better than those described in the long-term
follow-up of the MEPEX trial (median follow-up 3.41 vs.
3.95 years, during which time there were 38 (40.4 %) of
94 and 35 (50.7 %) of 69 deaths in our study and the
MEPEX trial, respectively [6]). The important differences
between our study and the MEPEX trial include the use
of intravenous CYC in the majority of our patients, while
only oral CYC was used in the older MEPEX trial; in
addition, we enrolled patients with (sometimes severe)
AH in our study. The lower cumulative dose of CYC
achieved with its intravenous use may have contributed
to better patient outcomes. This was also demonstrated
in another retrospective study by Pepper et al. on the
use of PLEX and intravenous CYC, in which only pa-
tients requiring dialysis were included [11]. Our patients’
1-year survival rate was lower than that in the study by
Pepper et al, but their study period (2005–2010) and pa-
tients’ characteristics (percentage of patients with AH,
percentage of ANCA subtypes) differed. Interestingly,
we did not find any difference in the survival of patients
with vs. without AH, although the patients with AH
were similarly distributed among those dialysed and
those not dialysed (data not shown). While the overall
mortality was associated with the degree of renal insuffi-
ciency in a previous retrospective study on AH [12], in
our study no difference in survival between patients re-
quiring vs. not requiring dialysis at presentation was
found, and the only factor clearly negatively influencing
prognosis in both studies was increasing age.
In our centre, during the whole study period, PLEX
was routinely used for (almost) all patients presenting
with renal failure and the vast majority of patients pre-
senting with AH. Thus, we were not able to use a
matched control group of patients not treated with
PLEX, as this would certainly have been subject to bias.
While researchers in a recent single-centre study found
no significant difference between groups with vs. without
PLEX [13], the authors of a meta-analysis of previously
published studies [14] concluded that PLEX in either
renal vasculitis or idiopathic rapidly progressive glomer-
ulonephritis may decrease the composite end point of
end-stage renal disease or death, but the effect of PLEX
for death alone was not significant (RR 1.01, 95 % CI
0.71–1.4, p = 0.9), and the authors admitted having in-
sufficient statistical information, given the relative lack
of data.
The renal survival results in our study were also simi-
lar to previously published data [6, 11]. In some studies,
researchers have found that the efficacy of PLEX may be
related to ANCA specificity (advantageous effect ob-
served in PR3-ANCA-positive patients) [15], while other
studies did not confirm that observation [16], in accord-
ance with our results, even though we did not use PLEX
in patients with better-preserved renal function. Interest-
ingly, we found that higher DEI (influenced by extrarenal
involvement) tended to be associated with better renal
survival, suggesting that extrarenal symptoms may en-
able earlier diagnosis, which is probably crucial for
favourable long-term outcomes of patients with AAV. In
line with this hypothesis, the number of patients dialysed
at entry was less in patients with higher DEI in this
study, even though this observation is limited by the fact
that the role of DEI as an independent predictor of end-
stage renal disease was not confirmed in the multivariate
analysis.
The safety of PLEX remains an important issue. In this
study, we did not observe any death or major adverse
events directly related to PLEX. In theory, PLEX may
lead to removal of coagulation factors and to worsening
of AH. Nevertheless, this may be prevented by a substi-
tution of fresh frozen plasma at the end of PLEX [17]. In
our study, infection, and not active vasculitis, was the
most common cause of death, which is consistent with
previous reports [18], suggesting that our current treat-
ment strategies are efficacious but may be too aggressive
in some patients. Surprisingly, even in patients treated
with rituximab in a randomised trial [19], the rate of ad-
verse events was not lower than in CYC/azathioprine-
treated patients, which implies that high-dose corticoste-
roids may also play an important role in treatment
toxicity.
On one hand, we are aware of possible limitations of
this study, caused mainly by its retrospective nature and
the lack of a control group, as discussed above. On the
other hand, we present data on a relatively large popula-
tion of patients from a single centre that largely confirm
the results of previous studies. The use of the DEI in-
stead of the more routinely used BVAS might have influ-
enced the assessment of activity and its potential
relationship; however, especially in patients diagnosed a
long time ago, the retrospective BVAS assessment may
not be valid. In patients with suspected AH, we always
tried to exclude infection or other causes of bleeding,
but it possible that misclassification might have occurred
in some patients.
Conclusions
Our results show that mortality of patients presenting
with severe manifestations of AAV remains high despite
the use of PLEX. Older age at presentation is associated
with worse prognosis. Higher DEI with extrarenal in-
volvement may enable earlier diagnosis and improve
renal survival, even though the independent predictive
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value of DEI has not been confirmed in our multivariate
analysis.
The prognosis of AAV seems to have been improving
in recent decades [20], including the severe manifesta-
tions [12], and it is currently unclear to what extent
PLEX contributes to this process [17]. Hopefully, the on-
going PEXIVAS trial will shed more light on the indica-
tions for PLEX in patients with AAV, particularly the
role of PLEX in patients with non-dialysis-dependent
renal failure and in patients with AH.
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